Greenwich LifeSciences, Inc.
GLSIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Greenwich LifeSciences, Inc. (GLSI) is listed under Biotechnology. With a market capitalization of $239.5M, it sits in micro-cap territory. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Market Cap
$239.5M
Beta
1.39
P/E (TTM)
—
P/E (Fwd)
-19.90
EPS (TTM)
$-1.38
EPS (Fwd)
$-0.82
ROE
-676.7%
ROA
-211.3%
Cash
$10.5M
Total Debt
$0
Free CF
-$3.4M
52W Change
40.8%
Annual Financials
Cash vs Debt
Greenwich LifeSciences, Inc. reports $10.5M in cash and $0 in total debt. Free cash flow is running at -$3.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -676.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Greenwich LifeSciences, Inc.'s trajectory.